SI2099489T1 - Sestavki in postopki za zdravljenje neoplazme - Google Patents

Sestavki in postopki za zdravljenje neoplazme

Info

Publication number
SI2099489T1
SI2099489T1 SI200731500T SI200731500T SI2099489T1 SI 2099489 T1 SI2099489 T1 SI 2099489T1 SI 200731500 T SI200731500 T SI 200731500T SI 200731500 T SI200731500 T SI 200731500T SI 2099489 T1 SI2099489 T1 SI 2099489T1
Authority
SI
Slovenia
Prior art keywords
neoplasm
compositions
treating
methods
Prior art date
Application number
SI200731500T
Other languages
English (en)
Slovenian (sl)
Inventor
Robert D. Mass
Gregory D. Plowman
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of SI2099489T1 publication Critical patent/SI2099489T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200731500T 2006-12-11 2007-05-04 Sestavki in postopki za zdravljenje neoplazme SI2099489T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm
EP07761925.2A EP2099489B1 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (1)

Publication Number Publication Date
SI2099489T1 true SI2099489T1 (sl) 2014-09-30

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731500T SI2099489T1 (sl) 2006-12-11 2007-05-04 Sestavki in postopki za zdravljenje neoplazme

Country Status (17)

Country Link
US (1) US20100086544A1 (OSRAM)
EP (1) EP2099489B1 (OSRAM)
JP (1) JP2010512407A (OSRAM)
KR (1) KR101320198B1 (OSRAM)
CN (1) CN101547705B (OSRAM)
AU (1) AU2007333565A1 (OSRAM)
BR (1) BRPI0717688A2 (OSRAM)
CA (1) CA2670707A1 (OSRAM)
DK (1) DK2099489T3 (OSRAM)
IL (1) IL198852A (OSRAM)
MX (1) MX2009006202A (OSRAM)
NZ (1) NZ577058A (OSRAM)
RU (1) RU2482877C2 (OSRAM)
SG (1) SG177891A1 (OSRAM)
SI (1) SI2099489T1 (OSRAM)
WO (1) WO2008073509A2 (OSRAM)
ZA (1) ZA200903489B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012088438A1 (en) * 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
AU2013232208B2 (en) * 2012-03-14 2017-04-27 Indiana University Research And Technology Corporation Compounds and methods for treating leukemia
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
NZ739026A (en) 2015-07-27 2019-03-29 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PL3330259T3 (pl) 2015-07-27 2021-02-08 Chong Kun Dang Pharmaceutical Corp. Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca
KR101799005B1 (ko) 2015-07-27 2017-11-17 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
BR112018002304B1 (pt) 2015-08-04 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
WO2017065473A1 (en) 2015-10-12 2017-04-20 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
MX2021014315A (es) 2019-05-31 2022-01-04 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de 1,3,4-oxadiazol homoftalimida como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
DE59906030D1 (de) * 1998-09-25 2003-07-24 Boehringer Ingelheim Pharma Neue substituierte indolinone mit einer inhibierenden wirkung auf verschiedene kinasen und cyclin/cdk-komplexe
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體

Also Published As

Publication number Publication date
WO2008073509A3 (en) 2009-01-08
WO2008073509A2 (en) 2008-06-19
MX2009006202A (es) 2009-06-22
KR20090087908A (ko) 2009-08-18
ZA200903489B (en) 2010-08-25
NZ577058A (en) 2012-04-27
JP2010512407A (ja) 2010-04-22
EP2099489B1 (en) 2014-05-21
IL198852A0 (en) 2011-08-01
DK2099489T3 (da) 2014-08-18
CN101547705A (zh) 2009-09-30
RU2482877C2 (ru) 2013-05-27
BRPI0717688A2 (pt) 2013-01-22
IL198852A (en) 2013-06-27
RU2009126588A (ru) 2011-01-20
AU2007333565A1 (en) 2008-06-19
EP2099489A2 (en) 2009-09-16
US20100086544A1 (en) 2010-04-08
CN101547705B (zh) 2013-06-12
KR101320198B1 (ko) 2013-10-30
CA2670707A1 (en) 2008-06-19
SG177891A1 (en) 2012-02-28
HK1131064A1 (en) 2010-01-15

Similar Documents

Publication Publication Date Title
ZA200903489B (en) Compositions and methods for treating a neoplasm
IL257681A (en) Methods and compositions for the treatment of cancer
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
IL193014A0 (en) Methods and compositions for treating schizophrenia
ZA200902860B (en) Compositions and methods for binding sphingosine-1-phosphate
IL198851A0 (en) Methods for treating hypercholesterolemia
EP2078522A4 (en) COMPOSITION FOR THE TREATMENT OF ALLERGIES
ZA200900140B (en) Methods and compositions for treating biofilms
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
GB0906630D0 (en) Compositions and method for hair loss prevention
EP2015765A4 (en) METHODS AND COMPOSITIONS FOR TREATING CONDITIONS
ZA200900243B (en) Methods and composition for treating a material
IL210097A0 (en) Compositions and methods for treating unfluenza
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
MY157996A (en) Desulfurizing coke-water salurry and process for preparation thereof
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
GB0621203D0 (en) PLK inhibitors
PL2132251T3 (pl) Kompozycja i sposób
EP2016706A4 (en) METHOD AND ARRANGEMENT FOR VIRTUAL MEETING
GB0625208D0 (en) Composition and method
GB0620930D0 (en) Composition and method for use thereof
EP2094279A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA
GB0600261D0 (en) Composition and method
GB0605004D0 (en) Composition and process
GB0607488D0 (en) Composition and process